Oaktree Acquisition Corp. III Life Sciences announced that starting December 16, 2024, holders of units from its initial public offering can separately trade Class A ordinary shares and warrants. Units will continue trading on Nasdaq as 'OACCU', while separated Class A shares and warrants will trade under 'OACC' and 'OACCW' respectively.
To separate units, holders must contact Continental Stock Transfer & Trust Company. Only whole warrants will trade, with no fractional warrants issued. The initial offering was underwritten by Jefferies , Citigroup Global Markets Inc., and UBS Investment Bank as joint book-running managers. The SEC declared the registration statement effective on October 23, 2024.
Oaktree Acquisition Corp. III Life Sciences has announced the pricing of its initial public offering (IPO) of 17,500,000 units at $10.00 per unit, totaling $175 million. The units will trade on Nasdaq under OACCU starting October 24, 2024. Each unit includes one Class A ordinary share and one-fifth of a redeemable warrant. Whole warrants allow holders to purchase shares at $11.50 each. The company granted underwriters a 45-day option to purchase up to 2,625,000 additional units. Jefferies, Citigroup, and UBS Securities are serving as joint book-running managers.